BaCkground: There is a lack of evidence to support acyclovir administration in pityriasis rosea. oBjeCtive: To determine the efficacy of acyclovir in patients with typical pityriasis rosea. Methods: A systematic review and meta-analysis of experimental studies was performed in MEDLINE, SCOPUS, EMBASE and others, from January 1990 to October 2016 on acyclovir for pityriasis rosea. Random effect model was used to find the pooled Risk Ratio. Outcomes, evaluated between weeks 1 to 8, were regression of lesions, cessation of lesions, decrease of symptoms and duration of disease. Comparisons were acyclovir vs. placebo; acyclovir vs. symptomatic treatment; acyclovir vs. antibiotic; acyclovir vs. observation and combined therapy (acyclovir plus symptomatic treatment) vs. symptomatic treatment alone. results: Seven papers were analyzed with 324 participants, of which 159 received acyclovir and 165 were controls. Acyclovir was superior to placebo for complete regression of lesions at week 1 (Risk Ratio 5.72, CI95% 2.36-13.88). However, combined therapy was not superior to symptomatic treatment at week 4 (Risk Ratio 1.46, CI95% 0.93-2.29). Individual studies showed the superiority of acyclovir for the control of symptoms and pruritus. study liMitations: We faced differences designs of trials and inconsistency between reports. ConClusion: Symptomatic treatment is a reasonable option for pityriasis rosea, and the addition of acyclovir is justified for the control of symptoms and pruritus. Keywords: Acyclovir; Histamine antagonists; Meta-analysis as topic; Pityriasis rosea; Pruritus 
INTRODUCTION
Pityriasis rosea (PR) is an acute inflammatory skin disease that occurs worldwide, more often in children and young people. 1, 2 Typically, an exanthema of smaller patches develops across the trunk, that usually lasts 8 weeks, with moderate to severe pruritus. 3, 4 The etiology is still unclear, but many features suggest a viral infectious cause: at least half of patients reports symptoms compatible with a viral upper respiratory infection, the early age of onset, the self-limited clinical course and the low rate of relapses. 5, 6 Accordingly, several authors have found the presence of Human Herpes Virus type 6 and 7 (HHV-6 and HHV-7) in patients with PR, however, the evidence is not enough to confirm a direct association. 4, 7, 8 Current treatments consist on topical and systemic therapy, mainly as symptomatic drugs, as PR is a self-limited disease. 9 Yet, Drago et al, 10 first described the efficacy of acyclovir for PR with Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot were not included in the initial search. There are no restrictions of language to select the studies for this review. We excluded studies lacking complete data in any arm of study, after exhausting efforts to contact the authors for full data.
Eligibility criteria
Overlapping studies were included after discarding the one with the smaller study population.
The comparisons were (1 They independently collected the data using a standardized data sheet. Both authors confirmed all entries and checked at least twice for completeness and accuracy. Disagreements were resolved by discussion with a third reviewer (HG). Authors were contacted by email for missing data and clarifications, in order to achieve completeness of studies.
Data analysis
The pooled relative risk (RR) was the effect measured of the primary outcome, with 95% confidence intervals (95%CI). As the heterogeneity was considerable, the pooled RR was calculated based on a random effect model, according to the 'standard approach'. 18 Statistical heterogeneity was assessed with the I 2 statistic. 19 For secondary outcomes, dichotomous data was calculated using RR and continuous data using the standardized mean difference, with 95%CI and a random effect model.
Included trials were characterized with descriptive statistics (percentages and mean). We performed analyses with Stata13 ® and
RevMan 5.1 ® .
Quality assessment
Every study was independently evaluated for `risk of bias´ by two reviewers (MR and NT), considering the domains and criteria suggested by the Cochrane Handbook v.5.1.0.. 12 Disagreements were discussed and resolved with a third reviewer (HG).
Other analysis
Subgroup analysis, publication bias and sensitivity analysis were not possible due to the limited number of trials in the meta-analysis.
RESULTS
The literature search yielded 104 titles and abstracts, and after eligibility criteria, 7 trials entered to systematic review and meta-analysis ( Figure 1 ). Characteristics of included trials are detailed in table 1. There were a total of 324 participants with PR, 159 on acyclovir and 165 controls. All studies had two arms, acyclovir and control groups. Only two studies used low doses of acyclovir (400mg 5 times daily), while the rest used high doses (800mg 5 times daily). 20, 21 Almost all of the studies had an intervention of seven days, except one (10 days). 22 All studies include male and females patients with a mean age of 26.9 years old. The rest of analyses are not presented, as there was not data available.
Main outcome analysis

DISCUSSION
Regression of lesions
This is the first meta-analysis that evaluates the efficacy of acyclovir for PR. We found that acyclovir was superior to placebo for PR at week 1 for achieving regression of lesions; but when combined with symptomatic treatment, acyclovir was not superior to control at week 4 (Figures 2 and 3 ). Several studies have linked PR to HHV-6 and 7 as main etiology. 5, 7 However, studies are not conclusive yet, as some have proposed other etiologies, such as other viruses (e.g.
HHV-8, cytomegalovirus, Epstein-Barr virus, etc.), association with bacterial and fungal infections, and even immunological origin. 26 We believe that most of the patients responded to the antiviral when compared to placebo due to the involvement of HHV-6 and 7 (Figure 2). Still, some authors have questioned acyclovir efficacy against HHV-7, as it lacks the thymidine kinase gene. 27 
A B
When acyclovir was compared with symptomatic treatment, this superiority for regression of lesions was apparently reduced ( Figure 3) . 20, 24 Thus, symptomatic treatment has an important role for the control of lesions in PR. Guidelines support the use of symptomatic treatment for PR with mild to moderate symptoms. 9, 11 However, a prior meta-analysis found inadequate evidence for efficacy of most symptomatic treatments. 17 Only a single study showed that oral antihistamine alone was superior than the combination of oral antihistamine and steroids in clearing the PR rash within two weeks. 29 The symptomatic treatment used in the studies included was oral antihistamine plus topical calamine or corticoid. We suggest that oral antihistamines should be included as primary symptomatic treatment, in association with topical steroids or calamine lotion.
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Control of symptoms
One study 10 demonstrated that acyclovir was superior to placebo for decreasing symptoms at week 1 and 2 ( Figure 5) ; another study showed the significant decrease of itching from week 1 to 4 with combined treatment. 20 It is important to underline that other reports had elucidated the anti-pruritic effect of acyclovir in PR. 9 Other treatments, erythromycin and phototherapy, have been also proposed for pruritic management in PR with controversial results. 31 Most of the guidelines suggest that, as PR is a self-limited illness, most patients do not need to be treated. Other authors propose that patients with recalcitrant symptoms, such as pruritus, are the exception: they may benefit from treatment with macrolides, phototherapy and antivirals. weeks. 32 Nevertheless, this study had methodological deficiencies in randomization, allocation concealment and analysis, with the adverse events inherent to macrolides. 33 Other studies suggested immunomodulatory and anti-inflammatory effects of macrolides in PR due to Chlamydia, Legionella and Mycoplasma involvement, but not assertively. [34] [35] [36] Clinical trials have shown that efficacy of macrolides, such as erythromycin, clarithromycin and azithromycin has not been proven. [36] [37] [38] One study compared acyclovir vs. erythromycin and showed that the antiviral was significantly superior for regression of lesions, but not significant for decrease of symptoms. 22 Therefore, we recommend the use of antiviral over macrolides supported by the possible viral etiology of PR. 39 Phototherapy with narrowband UVB and UVA1 has been proposed as methods to control PR severity and pruritus. 40, 41 Other to change itch and course of the disease. 42, 43 There is inadequate evidence for phototherapy, and sessions are given thrice a week for at least one month. 27 Although it might be efficient, it may not be feasible and accessible for all patients. 31 Based on the results, we think that symptomatic treatment (oral antihistamines and topical steroids/calamine) may be considered as baseline treatment for PR, and the early addition of acyclovir for pruritus control, especially in extensive, relapsing or persistent disease. 11, 17, 44 Other outcomes Acyclovir was not superior to placebo, neither combined to Figure 4 ). In addition, acyclovir failed to decrease significantly the duration of PR compared to placebo. However, studies that entered into the meta-analysis had opposed results independently ( Figure 6 ). 10, 25 Clinical trials included were not enough to distinguish efficacy of children from adult population. Drago et al. have found different characteristics between them. 45 Children have less prevalence of systemic symptoms and less average duration of exanthema. Therefore, we believed that acyclovir in children may not be a reasonable alternative for PR, until trials demonstrate efficacy in this population.
Adverse events
Adverse events were reported in both acyclovir and control groups ( Table 2 ). In an observer-blinded trial, 8 patients on acyclovir and antihistamines reported increased sleep, headache, nausea, vomiting and dysgeusia. 20 These adverse events, although they are expected in patients on acyclovir, were not reported in the rest of trials. 46 A triple-blinded trial reported abdominal pain and diarrhea in placebo group, possibly due to nocebo effect. 25, 47 Risk of bias Unclear risk of bias was prevalent for allocation concealment (selection bias) and incomplete outcome data (attrition bias) ( Figure 7A ). The rest of domains had in general low risk of bias.
Drago et al, 10 did not perform randomization neither allocation concealment. Two trials failed to blind participants from treatment received ( Figure 7B ).
20, 24
Limitations
We faced several limitations. First, studies did not evaluate all outcomes and they differed in temporality. Therefore, meta-analysis was not possible for all outcomes and weeks of the follow-up.
Second, some studies had high risk of bias in randomization and allocation concealment. However, we decided to include all trials since they represent interventional studies with similar established outcomes. Finally, there were few trials for each comparison, thus, subgroup analysis was not possible. Our results reflect that symptomatic treatment, as oral antihistamines and topical steroids/calamine, plays an important role for PR in the regression of lesions, given that there was no difference 
